This activity has expired. Thank you for using WebBasedCME.com. Continue to check our activities page for additional online CME offerings .


Post-Test - Prospects for GLP-1 Receptor Agonists: When, Who, and How to Treat


INSTRUCTIONS: Select the most appropriate response. To receive credit, participants must earn a score of 80% or higher.

0. Have you created an account on WebBasedCME.com? You must register and be signed in to participate and receive CME credit for this activity.



1. The ______________ incretin effect in type 2 diabetes (T2DM) is evident in the _______________insulin response following oral administration of glucose.
A: Decreased, decreased
B: Increased, increased
C: Increased, decreased
D: Decreased, increased

2. Which of the following is most likely to be evident in prediabetes?
A: Decreased insulin secretion
B: Increased fasting glucose levels
C: Increased postprandial glucose levels
D: Decreased insulin resistance

3. GLP-1 infusion is associated with a glucose-dependent increase in :
A: Insulin secretion
B: Postprandial glucose excursions
C: Glucagon secretion
D: ß-cell apoptosis

4. Based on clinical studies, which of the following is true regarding the effects of GLP-1 receptor agonists compared with insulin?
A: Liraglutide is less effective than insulin for lowering A1C
B: Exenatide is less effective than insulin for lowering A1C
C: GLP-1 receptor agonists and insulin have similar effects on ß-cell function
D: GLP-1 receptor agonists promote greater weight loss than insulin therapy

5. According to American Diabetes Association guidelines, which of the following patient characteristics would provide rationale for a less aggressive A1C goal > 7.0%?
A: Newly diagnosed T2DM
B: No comorbid conditions
C: Thin, non-obese patient
D: Known coronary artery disease

6. Which of the following is true regarding hypoglycemia and GLP-1 receptor agonists?
A: Hypoglycemia is likely if the patient fails to eat after injecting the medication
B: The incidence of hypoglycemia is significantly higher when GLP-1 receptors are used along with thiazolidinediones (TZD’s)
C: The incidence of hypoglycemia is low except when GLP-1 receptor agonists are used along with sulfonylureas
D: GLP-1 receptor agonists should not be used in elderly patients due to their higher rate of hypoglycemia in this population

7. If a patient experiences nausea that lasts into the second week of therapy with a GLP-1 receptor agonist, they are unlikely to improve, and alternate therapy should be initiated.
A: True
B: False

8. Which of the following is FALSE regarding storage of GLP-1 receptor agonist pens?
A: New, unopened pens should be stored in the refrigerator
B: The pen should be used with 29, 30, or 31-gauge pen needles
C: It is acceptable to re-use pen needles for up to two days
D: Medication should be protected from light when not in use

9. Monotherapy with a GLP-1 receptor agonist is NOT currently an appropriate option in which of the following situations?
A: GFR of 45 mL/min and A1C of 7.4%
B: History of severe hypoglycemia with sulfonylurea therapy
C: Diabetes duration of two years
D: T2DM for 10 years and A1C of 11% on metformin and pioglitazone maximum dosages

10. In clinical trials of patients with T2DM, GLP-1 receptor agonists have improved glycemic control in combination with the following agents EXCEPT?
A: DPP-4 inhibitors
B: Sulfonylureas
C: Metformin
D: Thiazolidinediones (TZD’s)

Return to Activity